• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Atrial fibrillation - Articles and news items

Atrial fibrillation market will peak in 2022 before decline to $4.9 Billion by 2025, says GlobalData

Atrial fibrillation market will peak at $11.8 billion in 2022

Industry news / 2 August 2016 / GlobalData

The atrial fibrillation market will expand from approximately $8 billion in 2015 to hit its peak of $11.8 billion in 2022, after which the impact of patent expiries will see the market value fall rapidly to $4.9 billion by 2025, according to research and consulting firm GlobalData…

vte

Daiichi Sankyo helps raise awareness of VTE and AF

Industry news / 13 October 2015 / Daiichi Sankyo

Daiichi Sankyo has teamed up with World Thrombosis Day to promote awareness of thrombosis, its causes, risk factors, and signs and symptoms…

edoxaban

Daiichi Sankyo’s edoxaban launched in the UK

Industry news / 10 July 2015 / Victoria White

Edoxaban, a new blood-thinning drug therapy to help prevent stroke in patients with non-valvular atrial fibrillation, has been launched in the UK…

Lixiana

Swissmedic approves Lixiana for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation

Industry news / 15 April 2015 / Daiichi Sankyo

Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation…

AF Patients fail to receive recommended treatment

Many AF patients at high risk of stroke fail to receive guideline-recommended oral anticoagulant treatment

Industry news / 17 March 2015 / Victoria White

AF patients considered at high risk for stroke may not be receiving recommended treatment as revealed in analyses from the GLORIA™-AF Registry Program…

Daiichi Sankyo logo

U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk

Industry news, News / 9 January 2015 / Daiichi Sankyo

U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism…

Daiichi Sankyo logo

Daiichi Sankyo launches new formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan

Industry news / 8 December 2014 / Daiichi Sankyo

Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA®60 mg Tablets…

Bristol Myers Squibb and Pfizer logo

Portola, Bristol-Myers Squibb and Pfizer announce statistically significant results from the first part of the Phase 3 ANNEXA™-A studies of investigational Andexanet Alfa with Eliquis (apixaban)

Industry news / 18 November 2014 / Bristol-Myers Squibb Company

Bristol-Myers Squibb Company and Pfizer Inc. announced results from the first part of the Phase 3 ANNEXA™-A (Andexanet Alfa a Novel Antidote to the Anticoagulant Effects of fXA Inhibitors – Apixaban) studies…

Boehringer Ingelheim logo

Pradaxa® (dabigatran etexilate) now approved in more than 100 countries for stroke prevention in atrial fibrillation

Industry news / 6 March 2014 / Boehringer Ingelheim

More than 100 countries have now approved Boehringer Ingelheim’s Pradaxa® for the prevention of stroke and systemic embolism for adult patients with the most common sustained heart rhythm condition…

Daiichi Sankyo logo

Daiichi Sankyo submits SAVAYSA(TM) (edoxaban) tablets New Drug Application to the U.S. FDA

Industry news / 9 January 2014 / Daiichi Sankyo

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism…

Daiichi Sankyo logo

Daiichi Sankyo submits supplemental New Drug Application in Japan for LIXIANA® (Edoxaban Tosilate Hydrate) for new indications

Industry news / 19 December 2013 / Daiichi Sankyo Company

Daiichi Sankyo is seeking approval in Japan for edoxaban in new indications for non-valvular atrial fibrillation (AF) and symptomatic venous thromboembolism…

Boehringer Ingelheim logo

New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years

Industry news / 19 November 2013 / Boehringer Ingelheim

Pradaxa® is the only novel oral anticoagulant with more than 6 years of long-term data supporting its beneficial role for stroke prevention…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +